Other equities research analysts have also recently issued research reports about the company. BTIG Research upped their price target on Orthopediatrics to $44.00 and gave the stock a buy rating in a research note on Friday, March 8th. Zacks Investment Research upgraded Orthopediatrics from a hold rating to a buy rating and set a $46.00 price target for the company in a research note on Saturday, March 16th. Finally, JMP Securities started coverage on Orthopediatrics in a research note on Wednesday, February 20th. They set an outperform rating and a $44.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Orthopediatrics presently has an average rating of Buy and a consensus target price of $41.00.
Orthopediatrics stock opened at $42.81 on Wednesday. Orthopediatrics has a 12 month low of $18.77 and a 12 month high of $47.82. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.54 and a quick ratio of 7.77. The company has a market cap of $599.19 million, a PE ratio of -44.59 and a beta of 0.04.
Several institutional investors have recently added to or reduced their stakes in the company. American International Group Inc. raised its stake in shares of Orthopediatrics by 10.2% during the first quarter. American International Group Inc. now owns 5,025 shares of the company’s stock worth $222,000 after purchasing an additional 465 shares during the last quarter. Rhumbline Advisers raised its position in Orthopediatrics by 6.6% in the first quarter. Rhumbline Advisers now owns 9,350 shares of the company’s stock worth $414,000 after acquiring an additional 580 shares in the last quarter. We Are One Seven LLC purchased a new position in Orthopediatrics in the fourth quarter worth $39,000. California State Teachers Retirement System raised its position in Orthopediatrics by 12.5% in the first quarter. California State Teachers Retirement System now owns 12,209 shares of the company’s stock worth $540,000 after acquiring an additional 1,361 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in Orthopediatrics by 83,150.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,665 shares of the company’s stock worth $74,000 after acquiring an additional 1,663 shares in the last quarter. Institutional investors and hedge funds own 44.89% of the company’s stock.
Orthopediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Read More: Green Investing
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.